Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA222873 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS)
| PRJNA222874 | ENA
Project description:PGRN: Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)
| PRJNA80257 | ENA
Project description:PGRN-RIKEN-CALGB 40101 - Genome-wide Pharmacogenomic Study of Cyclophosphamide, Doxorubicin and Paclitaxel in Breast Cancer
| PRJNA262703 | ENA
Project description:PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer
| PRJNA75655 | ENA
Project description:PGRN-RIKEN-CALGB 90401 - Genome-wide Pharmacogenomic Study of docetaxel and bevacizumab in Hormone Refractory Prostate Cancer
| PRJNA298270 | ENA
Project description:PGRN-RIKEN-CALGB 90401 - Genome-wide Pharmacogenomic Study of docetaxel and bevacizumab in Hormone Refractory Prostate Cancer
| PRJNA298271 | ENA
Project description:PGRN: Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)
| PRJNA80255 | ENA
Project description:Kynureninase is a member of a large family of catalytically diverse but structurally homologous pyridoxal 5'-phosphate (PLP) dependent enzymes known as the aspartate aminotransferase superfamily or alpha-family. The Homo sapiens and other eukaryotic constitutive kynureninases preferentially catalyze the hydrolytic cleavage of 3-hydroxy-l-kynurenine to produce 3-hydroxyanthranilate and l-alanine, while l-kynurenine is the substrate of many prokaryotic inducible kynureninases. The human enzyme was cloned with an N-terminal hexahistidine tag, expressed, and purified from a bacterial expression system using Ni metal ion affinity chromatography. Kinetic characterization of the recombinant enzyme reveals classic Michaelis-Menten behavior, with a Km of 28.3 +/- 1.9 microM and a specific activity of 1.75 micromol min-1 mg-1 for 3-hydroxy-dl-kynurenine. Crystals of recombinant kynureninase that diffracted to 2.0 A were obtained, and the atomic structure of the PLP-bound holoenzyme was determined by molecular replacement using the Pseudomonas fluorescens kynureninase structure (PDB entry 1qz9) as the phasing model. A structural superposition with the P. fluorescens kynureninase revealed that these two structures resemble the "open" and "closed" conformations of aspartate aminotransferase. The comparison illustrates the dynamic nature of these proteins' small domains and reveals a role for Arg-434 similar to its role in other AAT alpha-family members. Docking of 3-hydroxy-l-kynurenine into the human kynureninase active site suggests that Asn-333 and His-102 are involved in substrate binding and molecular discrimination between inducible and constitutive kynureninase substrates.
| S-EPMC2531291 | biostudies-literature
Project description:PGRN: Cholesterol and Pharmacogenetics Study (CAP)
| PRJNA156879 | ENA